Inhibition of multiple pathogenic pathways by histone deacetylase inhibitor SAHA in a corneal alkali-burn injury model

Molecular Pharmaceutics

Volumn 10, Issue 1, 2013, Pages 307-318

  Li, Xinyu ^a   Zhou, Qinbo ^b   Hanus, Jakub ^b   Anderson, Chastain ^b   Zhang, Hongmei ^a   Dellinger, Michael ^a   Brekken, Rolf ^a   Wang, Shusheng ^b,c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Tulane University   (United States)

^c TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

alkali burn injury; corneal neovascularization; HDAC; HDAC inhibitor; hemangiogenesis; inflammation; lymphangiogenesis

Indexed keywords

ALKALI; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; VORINOSTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORNEA BURN; CORNEA INJURY; CORNEA NEOVASCULARIZATION; DRUG MECHANISM; DRUG POTENCY; DRUG TOLERANCE; INFLAMMATION; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ALKALIES; ANIMALS; BURNS, CHEMICAL; CORNEA; CORNEAL DISEASES; CORNEAL NEOVASCULARIZATION; DISEASE MODELS, ANIMAL; EYE BURNS; GENE EXPRESSION; HISTONE DEACETYLASE INHIBITORS; HYDROXAMIC ACIDS; INFLAMMATION; LYMPHANGIOGENESIS; MALE; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84872142538     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp300445a     Document Type: Article

References (41)

1. Chang, J. H.; Gabison, E. E.; Kato, T.; Azar, D. T. Corneal neovascularization Curr. Opin. Ophthalmol. 2001, 12 (4) 242-249
2. Cursiefen, C.; Chen, L.; Borges, L. P.; Jackson, D.; Cao, J.; Radziejewski, C.; D'Amore, P. A.; Dana, M. R.; Wiegand, S. J.; Streilein, J. W. VEGF-A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment J. Clin. Invest. 2004, 113 (7) 1040-1050
3. Bock, F.; Onderka, J.; Dietrich, T.; Bachmann, B.; Pytowski, B.; Cursiefen, C. Blockade of VEGFR3-signalling specifically inhibits lymphangiogenesis in inflammatory corneal neovascularisation Graefe's Arch. Clin. Exp. Ophthalmol. 2008, 246 (1) 115-119
4. Sotozono, C.; He, J.; Matsumoto, Y.; Kita, M.; Imanishi, J.; Kinoshita, S. Cytokine expression in the alkali-burned cornea Curr. Eye Res. 1997, 16 (7) 670-676
5. Planck, S. R.; Rich, L. F.; Ansel, J. C.; Huang, X. N.; Rosenbaum, J. T. Trauma and alkali burns induce distinct patterns of cytokine gene expression in the rat cornea Ocul. Immunol. Inflammation 1997, 5 (2) 95-100
6. Sotozono, C.; He, J.; Tei, M.; Honma, Y.; Kinoshita, S. Effect of metalloproteinase inhibitor on corneal cytokine expression after alkali injury Invest. Ophthalmol. Vis. Sci. 1999, 40 (10) 2430-2434
7. Sakimoto, T.; Yamada, A.; Kanno, H.; Sawa, M. Upregulation of tumor necrosis factor receptor 1 and TNF-alpha converting enzyme during corneal wound healing Jpn. J. Ophthalmol. 2008, 52 (5) 393-398
8. Lu, P.; Li, L.; Liu, G.; Zhang, X.; Mukaida, N. Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist Invest. Ophthalmol. Vis. Sci. 2009, 50 (10) 4761-4768
9. Gupta, D.; Illingworth, C. Treatments for Corneal Neovascularization: A Review Cornea 2011, 30, 927-938
10. Haberland, M.; Montgomery, R. L.; Olson, E. N. The many roles of histone deacetylases in development and physiology: Implications for disease and therapy Nat. Rev. Genet. 2009, 10 (1) 32-42
11. Marks, P. A.; Xu, W. S. Histone deacetylase inhibitors: Potential in cancer therapy J. Cell Biochem. 2009, 107 (4) 600-608
12. Duvic, M.; Talpur, R.; Ni, X.; Zhang, C.; Hazarika, P.; Kelly, C.; Chiao, J. H.; Reilly, J. F.; Ricker, J. L.; Richon, V. M.; Frankel, S. R. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL) Blood 2007, 109 (1) 31-39
13. Marks, P. A.; Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug Nat. Biotechnol. 2007, 25 (1) 84-90
14. Finnin, M. S.; Donigian, J. R.; Cohen, A.; Richon, V. M.; Rifkind, R. A.; Marks, P. A.; Breslow, R.; Pavletich, N. P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 1999, 401 (6749) 188-193
15. Drummond, D. C.; Noble, C. O.; Kirpotin, D. B.; Guo, Z.; Scott, G. K.; Benz, C. C. Clinical development of histone deacetylase inhibitors as anticancer agents Annu. Rev. Pharmacol. Toxicol. 2005, 45, 495-528
16. Liu, T.; Kuljaca, S.; Tee, A.; Marshall, G. M. Histone deacetylase inhibitors: Multifunctional anticancer agents Cancer Treat. Rev. 2006, 32 (3) 157-165
17. Deroanne, C. F.; Bonjean, K.; Servotte, S.; Devy, L.; Colige, A.; Clausse, N.; Blacher, S.; Verdin, E.; Foidart, J. M.; Nusgens, B. V.; Castronovo, V. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling Oncogene 2002, 21 (3) 427-436
18. Kim, J. H.; Oh, M.; Yu, Y. S.; Kim, K. W.; Kwon, H. J. N-hydroxy-7-(2-naphthylthio) heptanomide inhibits retinal and choroidal angiogenesis Mol. Pharmaceutics 2009, 6 (2) 513-519
19. Shuttleworth, S. J.; Bailey, S. G.; Townsend, P. A. Histone Deacetylase inhibitors: New promise in the treatment of immune and inflammatory diseases Curr. Drug Targets 2010, 11 (11) 1430-1438
20. Blanchard, F.; Chipoy, C. Histone deacetylase inhibitors: New drugs for the treatment of inflammatory diseases? Drug Discovery Today 2005, 10 (3) 197-204
21. Kitano, A.; Okada, Y.; Yamanka, O.; Shirai, K.; Mohan, R. R.; Saika, S. Therapeutic potential of trichostatin A to control inflammatory and fibrogenic disorders of the ocular surface Mol. Vis. 2010, 16, 2964-2973
22. Glauben, R.; Siegmund, B. Inhibition of histone deacetylases in inflammatory bowel diseases Mol. Med. 2011, 17 (5-6) 426-433
23. Yoeruek, E.; Ziemssen, F.; Henke-Fahle, S.; Tatar, O.; Tura, A.; Grisanti, S.; Bartz-Schmidt, K. U.; Szurman, P. Safety, penetration and efficacy of topically applied bevacizumab: evaluation of eyedrops in corneal neovascularization after chemical burn Acta Ophthalmol. 2008, 86 (3) 322-328
24. Olsson, A. K.; Dimberg, A.; Kreuger, J.; Claesson-Welsh, L. VEGF receptor signalling-In control of vascular function Nat. Rev. Mol. Cell Biol. 2006, 7 (5) 359-371
25. Wang, S.; Li, X.; Parra, M.; Verdin, E.; Bassel-Duby, R.; Olson, E. N. Control of endothelial cell proliferation and migration by VEGF signaling to histone deacetylase 7 Proc. Natl. Acad. Sci. U.S.A. 2008, 105 (22) 7738-7743
26. Ha, C. H.; Jhun, B. S.; Kao, H. Y.; Jin, Z. G. VEGF stimulates HDAC7 phosphorylation and cytoplasmic accumulation modulating matrix metalloproteinase expression and angiogenesis Arterioscler., Thromb., Vasc. Biol. 2008, 28 (10) 1782-1788
27. Ha, C. H.; Wang, W.; Jhun, B. S.; Wong, C.; Hausser, A.; Pfizenmaier, K.; McKinsey, T. A.; Olson, E. N.; Jin, Z. G. Protein kinase D-dependent phosphorylation and nuclear export of histone deacetylase 5 mediates vascular endothelial growth factor-induced gene expression and angiogenesis J. Biol. Chem. 2008, 283 (21) 14590-14599
28. Zhou, Q.; Gallagher, R.; Ufret-Vincenty, R.; Li, X.; Olson, E. N.; Wang, S. Regulation of angiogenesis and choroidal neovascularization by members of microRNA-23∼27∼24 clusters Proc. Natl. Acad. Sci. U.S.A. 2011, 108 (20) 8287-8292
29. Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation Cold Spring Harbor Perspect. Biol. 2009, 1 (6) a001651
30. Bock, F.; Onderka, J.; Rummelt, C.; Dietrich, T.; Bachmann, B.; Kruse, F. E.; Schlotzer-Schrehardt, U.; Cursiefen, C. Safety profile of topical VEGF neutralization at the cornea Invest. Ophthalmol. Vis. Sci. 2009, 50 (5) 2095-2102
31. Kim, M. S.; Kwon, H. J.; Lee, Y. M.; Baek, J. H.; Jang, J. E.; Lee, S. W.; Moon, E. J.; Kim, H. S.; Lee, S. K.; Chung, H. Y.; Kim, C. W.; Kim, K. W. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes Nat. Med. 2001, 7 (4) 437-443
32. Alitalo, K.; Tammela, T.; Petrova, T. V. Lymphangiogenesis in development and human disease Nature 2005, 438 (7070) 946-953
33. Chen, L.; Hamrah, P.; Cursiefen, C.; Zhang, Q.; Pytowski, B.; Streilein, J. W.; Dana, M. R. Vascular endothelial growth factor receptor-3 mediates induction of corneal alloimmunity Nat. Med. 2004, 10 (8) 813-815
34. Cursiefen, C. Immune privilege and angiogenic privilege of the cornea Chem. Immunol. Allergy 2007, 92, 50-57
35. Achen, M. G.; Jeltsch, M.; Kukk, E.; Makinen, T.; Vitali, A.; Wilks, A. F.; Alitalo, K.; Stacker, S. A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4) Proc. Natl. Acad. Sci. U.S.A. 1998, 95 (2) 548-553
36. Jeltsch, M.; Kaipainen, A.; Joukov, V.; Meng, X.; Lakso, M.; Rauvala, H.; Swartz, M.; Fukumura, D.; Jain, R. K.; Alitalo, K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice Science 1997, 276 (5317) 1423-1425
37. Joukov, V.; Pajusola, K.; Kaipainen, A.; Chilov, D.; Lahtinen, I.; Kukk, E.; Saksela, O.; Kalkkinen, N.; Alitalo, K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases EMBO J. 1996, 15 (7) 1751
38. Choo, Q. Y.; Ho, P. C.; Tanaka, Y.; Lin, H. S. Histone deacetylase inhibitors MS-275 and SAHA induced growth arrest and suppressed lipopolysaccharide-stimulated NF-kappaB p65 nuclear accumulation in human rheumatoid arthritis synovial fibroblastic E11 cells Rheumatology (Oxford) 2010, 49 (8) 1447-1460
39. Li, X.; Stark, G. R. NFkappaB-dependent signaling pathways Exp. Hematol. 2002, 30 (4) 285-296
40. Sosne, G.; Christopherson, P. L.; Barrett, R. P.; Fridman, R. Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury Invest. Ophthalmol. Vis. Sci. 2005, 46 (7) 2388-2395
41. Wang, S.; Aurora, A. B.; Johnson, B. A.; Qi, X.; McAnally, J.; Hill, J. A.; Richardson, J. A.; Bassel-Duby, R.; Olson, E. N. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis Dev. Cell 2008, 15 (2) 261-271